Cargando…

The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer

OBJECTIVE: The aim of this study was to explore the value of the prostate-specific antigen (PSA) levels, the ratio of free PSA to total PSA (fPSA/TPSA), the PSA density (PSAD), digital rectal examination (DRE), transrectal prostate ultrasound (TRUS), and multiparameter MRI (MP-MRI) in the differenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Xiaojing, Jiang, Yumei, Zhang, Xinwei, Wang, Meiyu, Tian, Juanhua, Mu, Lijun, Du, Yuefeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414922/
https://www.ncbi.nlm.nih.gov/pubmed/32801907
http://dx.doi.org/10.2147/CMAR.S257769
_version_ 1783569070588690432
author Bai, Xiaojing
Jiang, Yumei
Zhang, Xinwei
Wang, Meiyu
Tian, Juanhua
Mu, Lijun
Du, Yuefeng
author_facet Bai, Xiaojing
Jiang, Yumei
Zhang, Xinwei
Wang, Meiyu
Tian, Juanhua
Mu, Lijun
Du, Yuefeng
author_sort Bai, Xiaojing
collection PubMed
description OBJECTIVE: The aim of this study was to explore the value of the prostate-specific antigen (PSA) levels, the ratio of free PSA to total PSA (fPSA/TPSA), the PSA density (PSAD), digital rectal examination (DRE), transrectal prostate ultrasound (TRUS), and multiparameter MRI (MP-MRI) in the differential diagnosis of benign prostatic hyperplasia (BPH) and prostate cancer (PCa). METHODS: From February 2016 to September 2019, data from 620 patients who underwent systematic transrectal ultrasound-guided prostate biopsy (STURS-PB) in our hospital were retrospectively collected, including the PSA levels, the fPSA/TPSA ratio, the PSAD, DRE, TRUS, MP-MRI, prostate volume, and other clinical data. RESULTS: Among the 620 patients, 249 patients were in the PCa group, and 371 patients in the BPH group. The positive puncture rate was 40.16%. The positive predictive values of DRE, TRUS, mpMRI, and TPSA levels for PCa were 39.91%, 39.38%, 64.14%, and 41.57%, respectively; the sensitivity of these parameters was 37.35%, 51.41%, 74.69%, and 57.43%, respectively; and the specificity of these parameters was 62.26%, 46.90%, 71.97%, and 45.82%, respectively. When the TPSA concentration was in the range of 4–20 ng/mL, the positive puncture rate of STURS-PB was 23.18%, with a high rate of misdiagnosis. When the TPSA concentration was in the range of 4–20 ng/mL, the fPSA/TPSA ratio was 0.15, the PSAD was 0.16, the comprehensive evaluation of PCa was optimal (the sensitivity of these parameters was 88.85% and 84.09%, respectively; the specificity was 80.17% and 67.29%, respectively; the positive predictive value was 57.41% and 51.39%, respectively). When the TPSA concentration >4 ng/mL, the fPSA/TPSA ratio ≤0.15 and the PSAD ≥0.16, the sensitivity, specificity, and correctness index of the PCa and BPH diagnosis were 80.54%, 82.75%, and 67.07%, respectively. CONCLUSION: When using DRE, TRUS, and MP-MRI to screen for PCa, MP-MRI has a relatively high sensitivity and specificity. Using these three thresholds (TPSA >4 ng/mL combined with an fPSA/TPSA ratio ≤0.15 and a PSAD ≥0.16) is significantly better than using TPSA levels alone for the differential diagnosis of PCa and BPH.
format Online
Article
Text
id pubmed-7414922
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74149222020-08-14 The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer Bai, Xiaojing Jiang, Yumei Zhang, Xinwei Wang, Meiyu Tian, Juanhua Mu, Lijun Du, Yuefeng Cancer Manag Res Original Research OBJECTIVE: The aim of this study was to explore the value of the prostate-specific antigen (PSA) levels, the ratio of free PSA to total PSA (fPSA/TPSA), the PSA density (PSAD), digital rectal examination (DRE), transrectal prostate ultrasound (TRUS), and multiparameter MRI (MP-MRI) in the differential diagnosis of benign prostatic hyperplasia (BPH) and prostate cancer (PCa). METHODS: From February 2016 to September 2019, data from 620 patients who underwent systematic transrectal ultrasound-guided prostate biopsy (STURS-PB) in our hospital were retrospectively collected, including the PSA levels, the fPSA/TPSA ratio, the PSAD, DRE, TRUS, MP-MRI, prostate volume, and other clinical data. RESULTS: Among the 620 patients, 249 patients were in the PCa group, and 371 patients in the BPH group. The positive puncture rate was 40.16%. The positive predictive values of DRE, TRUS, mpMRI, and TPSA levels for PCa were 39.91%, 39.38%, 64.14%, and 41.57%, respectively; the sensitivity of these parameters was 37.35%, 51.41%, 74.69%, and 57.43%, respectively; and the specificity of these parameters was 62.26%, 46.90%, 71.97%, and 45.82%, respectively. When the TPSA concentration was in the range of 4–20 ng/mL, the positive puncture rate of STURS-PB was 23.18%, with a high rate of misdiagnosis. When the TPSA concentration was in the range of 4–20 ng/mL, the fPSA/TPSA ratio was 0.15, the PSAD was 0.16, the comprehensive evaluation of PCa was optimal (the sensitivity of these parameters was 88.85% and 84.09%, respectively; the specificity was 80.17% and 67.29%, respectively; the positive predictive value was 57.41% and 51.39%, respectively). When the TPSA concentration >4 ng/mL, the fPSA/TPSA ratio ≤0.15 and the PSAD ≥0.16, the sensitivity, specificity, and correctness index of the PCa and BPH diagnosis were 80.54%, 82.75%, and 67.07%, respectively. CONCLUSION: When using DRE, TRUS, and MP-MRI to screen for PCa, MP-MRI has a relatively high sensitivity and specificity. Using these three thresholds (TPSA >4 ng/mL combined with an fPSA/TPSA ratio ≤0.15 and a PSAD ≥0.16) is significantly better than using TPSA levels alone for the differential diagnosis of PCa and BPH. Dove 2020-08-04 /pmc/articles/PMC7414922/ /pubmed/32801907 http://dx.doi.org/10.2147/CMAR.S257769 Text en © 2020 Bai et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Bai, Xiaojing
Jiang, Yumei
Zhang, Xinwei
Wang, Meiyu
Tian, Juanhua
Mu, Lijun
Du, Yuefeng
The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer
title The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer
title_full The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer
title_fullStr The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer
title_full_unstemmed The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer
title_short The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer
title_sort value of prostate-specific antigen-related indexes and imaging screening in the diagnosis of prostate cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414922/
https://www.ncbi.nlm.nih.gov/pubmed/32801907
http://dx.doi.org/10.2147/CMAR.S257769
work_keys_str_mv AT baixiaojing thevalueofprostatespecificantigenrelatedindexesandimagingscreeninginthediagnosisofprostatecancer
AT jiangyumei thevalueofprostatespecificantigenrelatedindexesandimagingscreeninginthediagnosisofprostatecancer
AT zhangxinwei thevalueofprostatespecificantigenrelatedindexesandimagingscreeninginthediagnosisofprostatecancer
AT wangmeiyu thevalueofprostatespecificantigenrelatedindexesandimagingscreeninginthediagnosisofprostatecancer
AT tianjuanhua thevalueofprostatespecificantigenrelatedindexesandimagingscreeninginthediagnosisofprostatecancer
AT mulijun thevalueofprostatespecificantigenrelatedindexesandimagingscreeninginthediagnosisofprostatecancer
AT duyuefeng thevalueofprostatespecificantigenrelatedindexesandimagingscreeninginthediagnosisofprostatecancer
AT baixiaojing valueofprostatespecificantigenrelatedindexesandimagingscreeninginthediagnosisofprostatecancer
AT jiangyumei valueofprostatespecificantigenrelatedindexesandimagingscreeninginthediagnosisofprostatecancer
AT zhangxinwei valueofprostatespecificantigenrelatedindexesandimagingscreeninginthediagnosisofprostatecancer
AT wangmeiyu valueofprostatespecificantigenrelatedindexesandimagingscreeninginthediagnosisofprostatecancer
AT tianjuanhua valueofprostatespecificantigenrelatedindexesandimagingscreeninginthediagnosisofprostatecancer
AT mulijun valueofprostatespecificantigenrelatedindexesandimagingscreeninginthediagnosisofprostatecancer
AT duyuefeng valueofprostatespecificantigenrelatedindexesandimagingscreeninginthediagnosisofprostatecancer